227 related articles for article (PubMed ID: 21649590)
1. [Pleiotropic effects of nicotinic acid therapy in men with coronary heart disease and elevated lipoprotein(a) levels].
Safarova MS; Trukhacheva EP; Ezhov MV; Afanas'eva OI; Afanas'eva MI; Tripoten' MI; Liakishev AA; Pokrovskiĭ SN
Kardiologiia; 2011; 51(5):9-16. PubMed ID: 21649590
[TBL] [Abstract][Full Text] [Related]
2. Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.
Davidson M; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Setze C; Carlson DM; Stolzenbach J
Cardiovasc Drugs Ther; 2012 Aug; 26(4):349-58. PubMed ID: 22622962
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
5. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
6. Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels.
Ezhov MV; Safarova MS; Afanasieva OI; Pogorelova OA; Tripoten MI; Adamova IY; Konovalov GA; Balakhonova TV; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():163-9. PubMed ID: 25936321
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
Li XP; Duan J; Zhao SP; Tan MY; Xu ZM; Zhang DQ
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(34):2399-403. PubMed ID: 17156651
[TBL] [Abstract][Full Text] [Related]
8. Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a).
Vavlukis M; Mladenovska K; Daka A; Dimovski A; Domazetovska S; Kuzmanovska S; Kedev S
Ann Pharmacother; 2016 Aug; 50(8):609-15. PubMed ID: 27242350
[TBL] [Abstract][Full Text] [Related]
9. [Changes of blood lipids in colorectal cancer patients with coronary heart disease and value of lipid-lowering therapy with statins].
Liang ZT; Wang XP; Zeng QT; Liao YH; Gao CY; Li MW
Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):863-5. PubMed ID: 18504222
[TBL] [Abstract][Full Text] [Related]
10. Predictors of anterior and posterior wall carotid intima media thickness progression in men and women at moderate risk of coronary heart disease.
Maki KC; Davidson MH; Dicklin MR; Bell M; Witchger M; Feinstein SB
J Clin Lipidol; 2011; 5(3):141-151. PubMed ID: 21600518
[TBL] [Abstract][Full Text] [Related]
11. Lowering of lipoprotein(a) level under niacin treatment is dependent on apolipoprotein(a) phenotype.
Artemeva NV; Safarova MS; Ezhov MV; Afanasieva OI; Dmitrieva OA; Pokrovsky SN
Atheroscler Suppl; 2015 May; 18():53-8. PubMed ID: 25936305
[TBL] [Abstract][Full Text] [Related]
12. Specific Lp(a) apheresis: A tool to prove lipoprotein(a) atherogenicity.
Pokrovsky SN; Afanasieva OI; Safarova MS; Balakhonova TV; Matchin YG; Adamova IYU; Konovalov GA; Ezhov MV
Atheroscler Suppl; 2017 Nov; 30():166-173. PubMed ID: 29096833
[TBL] [Abstract][Full Text] [Related]
13. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients--a controlled randomized trial.
Shukla A; Sharma MK; Jain A; Goel PK
Indian Heart J; 2005; 57(6):675-80. PubMed ID: 16521637
[TBL] [Abstract][Full Text] [Related]
14. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
15. Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia.
Maki KC; Bays HE; Dicklin MR; Johnson SL; Shabbout M
J Clin Lipidol; 2011; 5(6):483-92. PubMed ID: 22108152
[TBL] [Abstract][Full Text] [Related]
16. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.
Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN;
JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776
[TBL] [Abstract][Full Text] [Related]
17. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography.
Safarova MS; Ezhov MV; Afanasieva OI; Matchin YG; Atanesyan RV; Adamova IY; Utkina EA; Konovalov GA; Pokrovsky SN
Atheroscler Suppl; 2013 Jan; 14(1):93-9. PubMed ID: 23357149
[TBL] [Abstract][Full Text] [Related]
18. Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients.
Joy MS; Dornbrook-Lavender KA; Chin H; Hogan SL; Denu-Ciocca C
Ann Pharmacother; 2008 Jan; 42(1):9-15. PubMed ID: 18000162
[TBL] [Abstract][Full Text] [Related]
19. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ
J Am Coll Cardiol; 2010 Jun; 55(24):2721-6. PubMed ID: 20399059
[TBL] [Abstract][Full Text] [Related]
20. Lipid modifying action of atorvastatin in comparison to combination of atorvastatin and nicotinic acid in patients with ischaemic heart disease.
Santanu G; Suhrita P; Mookerjee S; Tania K; Mita S; Pramit G; Sharmila G; Miraj M; Debdutta M
Indian Heart J; 2011; 63(5):434-7. PubMed ID: 23550422
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
